Table 1.
Entry | ID# | Structure | % Inhibition & IC50a | Log IC50 ± Std. Error |
---|---|---|---|---|
1 | Vorapaxar | 95%; 0.032 μM |
− 7.5 ± 0.084 | |
2 | Atopaxar | 94%; 0.033 μM |
− 7.5 ± 0.10 | |
3 | RWJ-58259 11a |
94%; 0.020 μM |
− 7.7 ± 0.065 | |
4 | DG-207 12 |
76%; 0.29 μM |
− 6.5 ± 0.074 | |
5 | ML161 16 |
82%; 0.85 μM |
− 6.7 ± 0.099 | |
6 | CJD-125 17 |
74%; 3.16 μMb |
N.D. | |
7 | EMG-21 18 |
68%; 3.31 μM |
− 5.5 ± 0.26 | |
8 | EMG-23 19 |
49% | N.D. | |
9 | RR-90 21 |
77%; 0.97 μM |
− 6.0 ± 0.19 | |
10 | DG-5 26 |
77%; 94 μM |
− 4.0 ± 2.9 | |
11 | RR-10 20 |
79%; 81 μM |
− 4.0 ± 5.1 |
%Inhibition of PAR1 antagonists in presence of 5 μM TFLLRN-NH2. N.D. = not determined.
Estimated IC50 (incomplete curve at high concentration).